Thierry Ragot

Title: Thierry Ragot: Innovator in Antitumor Treatments

Introduction

Thierry Ragot is a notable inventor based in Meudon, France. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antitumor treatments. With a total of 3 patents to his name, Ragot's work focuses on utilizing recombinant adenoviruses for therapeutic purposes.

Latest Patents

One of Thierry Ragot's latest patents involves the creation of defective recombinant adenoviruses expressing cytokines for antitumor treatment. This patent describes a recombinant nucleic acid that facilitates the production of a defective adenovirus. The adenovirus contains an inserted sequence coding for a cytokine, which is regulated by a promoter within the genomic sequence. This innovative approach allows for the preparation of anti-tumoral drugs that can be directly injected into the tumor of the host, providing a targeted treatment option.

Career Highlights

Throughout his career, Thierry Ragot has worked with various esteemed organizations, including the Centre National de la Recherche Scientifique. His research has significantly advanced the understanding and application of recombinant technologies in medicine.

Collaborations

Thierry Ragot has collaborated with notable professionals in his field, including Michel Perricaudet and Hedi Mohamed Haddada. These collaborations have further enriched his research and contributed to the development of effective therapeutic strategies.

Conclusion

In summary, Thierry Ragot is a distinguished inventor whose work in the field of antitumor treatments has the potential to revolutionize cancer therapy. His innovative patents and collaborations highlight his commitment to advancing medical science.